The Latest Cardiac and Vascular News
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Cantor Global […]
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the following upcoming investor […]
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) — The Sarcomeric Human Cardiomyopathy Registry (SHaRe) and MyoKardia, Inc. (Nasdaq: MYOK) announced today the publication of results from a multicenter, international, longitudinal study of data from nearly 4,600 patients with […]
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Wedbush Pacgrow […]
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report second quarter 2018 financial […]
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the […]
SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the design of its pivotal Phase 3 EXPLORER-HCM clinical […]
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study […]
Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) —MyoKardia (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of […]
